Beijing Konruns Pharmaceutical Co., Ltd.SSE: 603590

Earnings Preannouncement for 2025

Jan 8, 2026 · Issued by Beijing Konruns Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 8, 2026

On 6ix: 6ix.com/news/earnings-preannouncement-for-2025-185

Earnings Preannouncement for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Beijing Konruns Pharmaceutical Co., Ltd. on 6ix

Earlier from Beijing Konruns Pharmaceutical

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025Jan 5
Announcement on Election of Employee DirectorDec 31, 2025
Announcement on FDA Approval for Clinical Trials of KC1086 ProjectDec 25, 2025
Announcement on Company Re-certified as High-tech EnterpriseDec 18, 2025
Announcement on Resolutions of the 18th Meeting of the 4th Board of SupervisorsDec 16, 2025

Later from Beijing Konruns Pharmaceutical

Announcement on Using Partial Idle Raised Funds for Cash Management and RedemptionFeb 5
Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid TumorsMar 5
Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic CarcinomaMar 19
Announcement on Canceling Special Accounts for Partial Raised Funds and Special Settlement Accounts for Cash ManagementMar 24
Announcement on Approval by CDE for the Key Phase III Clinical Study of KC1036 as a Second-Line Treatment for Advanced Esophageal Squamous Cell CarcinomaApr 10

All Beijing Konruns Pharmaceutical news releases

Follow Beijing Konruns Pharmaceutical into a list and get an email when it puts out news.

Follow Beijing Konruns Pharmaceutical